Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.24 USD
Change Today -0.10 / -4.27%
Volume 1.1M
BIOC On Other Exchanges
As of 5:20 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5810 Nancy Ridge Drive

San Diego, CA 92121

United States

Phone: 858-320-8200

Fax: 858-320-8225

Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) tests. The company’s tests provide information to oncologists that enable them to select the most appropriate treatment for their patients based on better, timelier and more-detailed data on the characteristics of tumors. The company’s OncoCEE-BR breast cancer test and its planned tests utilize its Cell Enrichment and Extraction (CEE) technology for the enumeration and analysis of CTCs, and its CEE-Selector technology for the detection and analysis of ctDNA, each performed on a standard blood sample. The company offers and conducts its breast cancer diagnostic tests and offers its clinical trial services at its Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified and College of American Pathologists (CAP)-accredited, and state-law licensed, laboratory. The company’s breast cancer test and its near-term cancer diagnostic tests and clinical trial services include the following: CTC and ctDNA Testing: The company’s breast cancer test and its other planned cancer diagnostic tests are based on its CEE and CEE-Selector technologies and are intended to be performed only in its clinical laboratory. Clinical Trial Services: The company intends to utilize its clinical laboratory and translational research capabilities to provide clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations to improve the efficiency and economic viability of their clinical trials. The company intends to commercialize cancer diagnostic tests in the United States as laboratory developed tests (LDTs) performed in its CLIA-certified laboratory. OncoCEE CTC Test: OncoCEE-BR OncoCEE-BR breast cancer test is the CTC test that the company has developed and offers it to physicians through CLIA laboratory. It is based on a standard blood sample and can be used at the time of diagnosis and for monitoring, including at the time of progression or recurrence. Other OncoCEE CTC Tests in Development These tests include OncoCEE-LU for lung cancer, OncoCEE-GA for gastric cancer, OncoCEE-CRTM for colorectal cancer, OncoCEE-PR for prostate cancer, and OncoCEE-ME for melanoma. OncoCEE-LU: The company’s OncoCEE-LU test would include various components: CTC enumeration, FISH analysis for echinoderm microtubule-associated protein-like 4/anaplastic lymphoma kinase (EML4/ALK) and ROS1 (c-ros oncogene 1, receptor tyrosine kinase), and potentially for ret proto-oncogene. OncoCEE-GA: The company is developing its OncoCEE-GA test for gastric cancer based on the identification of HER2 as a biomarker for this disease. Its OncoCEE-GA test would include CTC enumeration and HER2 analysis of CTCs by FISH. OncoCEE-CR: The company’s plan for its OncoCEE-CR test for colorectal cancer is to offer mutation testing analogous to that performed on lung cancer CTCs, namely detection of key mutations in the epidermal growth factor receptor (EGFR), K-ras and B-raf genes, along with CTC enumeration. OncoCEE-PR: The company’s OncoCEE-PR test for prostate cancer would be based on the analysis of CTCs found in a standard blood sample by FISH for key biomarkers: the androgen receptor, and phosphatase and tensin homolog. The test would also include CTC enumeration, and its CEE-Cap antibody capture cocktail would be modified from that used for breast and lung cancer to include prostate specific membrane antigen. Laboratory Testing From its CLIA laboratory in San Diego, California, the company intends to provide test results from its proprietary CTC and ctDNA tests to oncologists in community hospitals, cancer centers, group practices, and offices. Clinical Trials Services The company, in addition to testing for oncologists and their patients, plans to offer clinical trials testing services to help increase the viability of clinical trials for pharmaceutical and biopharmaceutical companies and clinical research organizations. Business Strategy The company plans to provide oncologists with a straightforward means to profile and ch

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOC:US $2.24 USD -0.10

BIOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Atossa Genetics Inc $1.80 USD -0.11
BioMerieux €90.10 EUR -0.90
Fluidigm Corp $42.10 USD -0.75
Illumina Inc $185.64 USD -1.98
Laboratory Corp of America Holdings $126.09 USD -1.19
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 78.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 203.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCEPT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at